Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion

Shimura, Masahiko; Yasuda, Kanako

doi:10.1136/bjophthalmol-2013-304720

Cited by 17 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, a lower number of reinjections were observed in the combined treatment [209]. The application of topical bromfenac, a nonsteroidal anti-inflammatory drug during IVB therapy in eyes with ME secondary to BRVO, was found to have the advantage of reducing the number of injections although it did not affect the visual prognosis [210]. Other combination therapies that have been investigated include corticosteroids with laser, anti-VEGF agents with corticosteroids, anti-VEGF agents with laser, and AVS or PPV with corticosteroids, to name a few [211–219].…”

Section: Treatmentmentioning

confidence: 99%

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

Paulus

Shuai

et al. 2017

Journal of Ophthalmology

View full text Add to dashboard Cite

For years, branch retinal vein occlusion is still a controversial disease in many aspects. An increasing amount of data is available regarding classification, pathogenesis, risk factors, natural history, and therapy of branch retinal vein occlusion. Some of the conclusions may even change our impression of branch retinal vein occlusion. It will be beneficial for our doctors to get a deeper understanding of this disease and improve the treatment skills. The aims of this review is to collect the information above and report new ideas especially from the past a few years.

show abstract

Section: Treatmentmentioning

confidence: 99%

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

Paulus

Shuai

et al. 2017

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated that bromfenac decreases eye pain and irritative symptoms following refractive surgery with no signals for increased rates of side effects or adverse changes in VA or healing/corneal epithelialization 61–66. Bromfenac has shown promise in reducing retinal thickening in patients with DME and has been reported to be beneficial in the management of uveitic macular edema when used in combination with IVTA or IVB including improvements in CMT and VA69 and reduced frequency of intravitreal injections 70. Results of several studies suggest that topical bromfenac may be beneficial in patients with anterior segment and/or inflammatory ocular surface disorders, including blepharitis,30 conjunctivitis/SAC/vernal keratoconjunctivitis, scleritis/episcleritis,30,77–79 dry eye disease,80 anterior uveitis,81 and corneal ulcer pain 23…”

Section: Discussionmentioning

confidence: 99%

“…The efficacy of bromfenac 0.1% in combination with IVB in 44 patients (48 eyes) with macular edema related to branch RVO was studied in a prospective case-control pilot study 70. Patients received IVB initially and repeated the treatment when macular edema (defined as foveal thickness ≥300 µm) recurred.…”

Section: Introductionmentioning

confidence: 99%

<p>Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies</p>

Schechter¹

2019

OPTH

View full text Add to dashboard Cite

Topical ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat postoperative inflammation and pain following cataract surgery and for treatment and prophylaxis of pseudophakic cystoid macular edema (CME). Bromfenac is a brominated NSAID with strong in vitro anti-inflammatory potency. Like other ophthalmic NSAIDs, bromfenac is often used outside of the cataract surgery setting. This paper provides an overview of bromfenac’s preclinical ocular pharmacology and pharmacokinetics, followed by a review of 23 published clinical studies in which various marketed bromfenac formulations were used for conditions other than cataract surgery or pseudophakic CME. These include: post-refractive eye surgery; macular edema associated with diabetes, uveitis, or retinal vein occlusion; inflammation associated with age-related macular degeneration; pain related to intravitreal injections; and other ocular anterior segment and surface disorders with an inflammatory component. The published evidence reviewed supports the safety and effectiveness of bromfenac in these additional ophthalmic indications. Bromfenac was well tolerated when given alone or in combination with intravitreal anti-vascular endothelial growth factor agents, topical corticosteroids, or topical mast-cell stabilizers. The most common adverse event reported was ocular irritation. No serious adverse events (ie, corneal epithelial disorders) were reported, although the majority of studies did not systematically evaluate potential side effects. Corneal complications, such as melts reported with diclofenac and ketorolac, were not observed with bromfenac in the studies. In summary, published study data support the clinical utility of bromfenac in various ocular disorders beyond post-cataract surgery. Additional studies are warranted to further define the potential role of bromfenac ophthalmic solution in clinical practice.

show abstract

“…Ponadto w leczeniu skojarzonym zaobserwowano mniejszą liczbę ponownych wstrzyknięć [26,33]. Stwierdzono, że zastosowanie miejscowo bromfenaku, niesteroidowego leku przeciwzapalnego, w oczach z obrzękiem plamki wtórnym do BRVO ma tę zaletę, że zmniejsza liczbę wstrzyknięć, chociaż nie wpływa na ostrość widzenia [26,34]. Inne badane terapie skojarzone to glikokortykosteroidy z laserem, preparaty anty-VEGF z glikokortykosteroidami, preparaty anty--VEGF z laserem i sheatotomia, czyli nacięcie pochewki naczyń (AVS) lub PPV z glikokortykosteroidami [26,[35][36][37][38][39][40][41][42][43].…”

Section: Laseroterapia W Cukrzycowym Obrzęku Plamkiunclassified

Zastosowanie laseroterapii w chorobach siatkówki. Część II

2020

View full text Add to dashboard Cite

Choroby siatkówki stanowią dużą grupę schorzeń narządu wzroku. W leczeniu wielu z nich od lat z powodzeniem jest stosowana laseroterapia. Mimo prób wprowadzania innych metod leczniczych nadal pozostaje ona jedną z głównych opcji terapeutycznych. W pracy przedstawiono przegląd piśmiennictwa dotyczący zastosowania laseroterapii w chorobach siatkówki, z uwzględnieniem nowych rodzajów i sposobów tej formy leczenia. Pracę podzielono na trzy części. W pierwszej, która ukazała się w poprzednim numerze, przedstawiono metodykę i rodzaje zabiegów laserowych. Część druga, publikowana w niniejszym numerze, zawiera przegląd piśmiennictwa dotyczący laseroterapii w retinopatii cukrzycowej, cukrzycowym obrzęku plamki oraz chorobach naczyniowych siatkówki. Trzecia część, która ukaże się w kolejnym numerze, zaprezentuje przegląd piśmiennictwa dotyczący laseroterapii w przedarciach oraz chorobach zwyrodnieniowych siatkówki, retinopatii wcześniaków, zwyrodnieniu plamki związanym z wiekiem oraz innych chorobach siatkówki.

show abstract

Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion

Abstract: UMIN 14929.

Cited by 17 publications

References 26 publications

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

<p>Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies</p>

Zastosowanie laseroterapii w chorobach siatkówki. Część II

Contact Info

Product

Resources

About